阅读说明：本技术 癫痫治疗剂 (Therapeutic agent for epilepsy ) 是由 东山浩之 协田久嗣 伊东义真 长田祥秀 于 2019-03-18 设计创作，主要内容包括：本发明提供了一种组合药剂,该组合药剂组合N-[(1S)-2,2,5,7-四氟-2,3-二氢-1H-茚-1-基]磺酰胺与AMPA型谷氨酸受体拮抗剂,如3-(2-氰基苯基)-5-(2-吡啶基)-1-苯基-1,2-二氢吡啶-2-酮或2-氟-6-(3-氟-8-氧代-7-(吡啶-3-基)-7,8-二氢-6H-吡喃并[3,2-b:5,4-b’]联吡啶-9-基)苯甲腈,并且该组合药剂具有用作用于癫痫的治疗剂的潜力。(The present invention provides a combination medicament combining N- [ (1S) -2,2,5, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl ] sulfonamide with an AMPA-type glutamic acid receptor antagonist, such as 3- (2-cyanophenyl) -5- (2-pyridyl) -1-phenyl-1, 2-dihydropyridin-2-one or 2-fluoro-6- (3-fluoro-8-oxo-7- (pyridin-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile, and which have potential for use as therapeutic agents for epilepsy.)

1. A therapeutic agent for epilepsy, which comprises N- [ (1S) -2,2,5, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl ] sulfonamide

Or a pharmaceutically acceptable salt thereof, and an AMPA-type glutamate receptor antagonist.

2. A therapeutic agent for epilepsy, which comprises N- [ (1S) -2,2,5, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl ] sulfonamide administered simultaneously or separately

Or a pharmaceutically acceptable salt thereof, and an AMPA-type glutamate receptor antagonist.

3. A therapeutic agent for epilepsy, which comprises N- [ (1S) -2,2,5, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl ] sulfonamide

Or a pharmaceutically acceptable salt thereof, and an AMPA-type glutamate receptor antagonist.

4. A therapeutic agent according to any one of claims 1 to 3, wherein the AMPA-type glutamate receptor antagonist is a compound selected from the group consisting of:

3- (2-cyanophenyl) -5- (2-pyridyl) -1-phenyl-1, 2-dihydropyridin-2-one,

9- (2-chlorophenyl) -7- (pyridin-3-yl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

2-fluoro-6- (7- (5-methoxypyridin-3-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

2-fluoro-6- (7- (6-methylpyridin-3-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

9- (2-chloro-3-fluorophenyl) -7- (6-methylpyridin-3-yl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

2-fluoro-6- (7- (2-methoxypyrimidin-5-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

7- (pyridin-3-yl) -9- (2,3,5, 6-tetrafluorophenyl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

3- (8-oxo-7- (thiophen-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyridinecarbonitriles,

3- (8-oxo-7- (thiophen-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyrazine-2-carbonitrile,

9- (2-fluorophenyl) -7-phenyl-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

2- (7- (4-fluorophenyl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

3- (7- (4-fluorophenyl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyridinecarbonitrile,

3- (7- (2-fluorophenyl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyridinecarbonitrile,

3- (3-fluoro-8-oxo-7-phenyl-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyridinecarbonitriles,

2-fluoro-6- (3-fluoro-8-oxo-7- (pyridin-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

2-fluoro-6- (7- (5-fluoropyridin-3-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

2-fluoro-6- (10-fluoro-3-oxo-4- (pyridin-3-yl) -4, 5-dihydro-3H-benzopyran [3,4-b ] pyridin-2-yl) benzonitrile,

9- (2-chloro-3-fluorophenyl) -7- (5-fluoropyridin-3-yl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

2-fluoro-6- (8-oxo-7- (pyrimidin-5-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

3, 6-difluoro-2- (8-oxo-7- (pyridin-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

2- (7- (5-chloropyridin-3-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) -6-fluorobenzonitrile,

2-fluoro-6- (7- (2-methylpyrimidin-5-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile, and

9- (3-fluoro-2-tolyl) -7- (pyridin-3-yl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

5. a therapeutic agent according to any one of claims 1 to 3, wherein the AMPA-type glutamate receptor antagonist is 3- (2-cyanophenyl) -5- (2-pyridinyl) -1-phenyl-1, 2-dihydropyridin-2-one

Or a pharmaceutically acceptable salt thereof.

6. A therapeutic agent according to any one of claims 1 to 3, wherein the AMPA-type glutamate receptor antagonist is a compound selected from the group consisting of:

9- (2-chlorophenyl) -7- (pyridin-3-yl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

2-fluoro-6- (7- (5-methoxypyridin-3-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

2-fluoro-6- (7- (6-methylpyridin-3-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

9- (2-chloro-3-fluorophenyl) -7- (6-methylpyridin-3-yl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

2-fluoro-6- (7- (2-methoxypyrimidin-5-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

7- (pyridin-3-yl) -9- (2,3,5, 6-tetrafluorophenyl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

3- (8-oxo-7- (thiophen-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyridinecarbonitriles,

3- (8-oxo-7- (thiophen-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyrazine-2-carbonitrile,

9- (2-fluorophenyl) -7-phenyl-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

2- (7- (4-fluorophenyl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

3- (7- (4-fluorophenyl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyridinecarbonitrile,

3- (7- (2-fluorophenyl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyridinecarbonitrile,

3- (3-fluoro-8-oxo-7-phenyl-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyridinecarbonitriles,

2-fluoro-6- (3-fluoro-8-oxo-7- (pyridin-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

2-fluoro-6- (7- (5-fluoropyridin-3-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

2-fluoro-6- (10-fluoro-3-oxo-4- (pyridin-3-yl) -4, 5-dihydro-3H-benzopyran [3,4-b ] pyridin-2-yl) benzonitrile,

9- (2-chloro-3-fluorophenyl) -7- (5-fluoropyridin-3-yl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

2-fluoro-6- (8-oxo-7- (pyrimidin-5-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

3, 6-difluoro-2- (8-oxo-7- (pyridin-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

2- (7- (5-chloropyridin-3-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) -6-fluorobenzonitrile,

2-fluoro-6- (7- (2-methylpyrimidin-5-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

And 9- (3-fluoro-2-tolyl) -7- (pyridin-3-yl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

7. the therapeutic agent according to any one of claims 1 to 3, wherein the AMPA-type glutamate receptor antagonist is 2-fluoro-6- (3-fluoro-8-oxo-7- (pyridin-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile

Or a pharmaceutically acceptable salt thereof.

Technical Field

The present invention relates to therapeutic agents for epilepsy that combine indan-1-ylsulfonamide derivatives and AMPA-type glutamate receptor antagonists. More particularly, the present invention relates to a therapeutic agent for epilepsy which combines N- [ (1S) -2,2,5, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl ] sulfonamide (or a pharmaceutically acceptable salt thereof) and an AMPA-type glutamate receptor antagonist.

Background

Epilepsy is one of the most common central nervous system disorders affecting more than 50000000 or more worldwide. WHO defines epilepsy as "a multi-etiology chronic brain disease characterized by recurrent seizures (seizures) due to excessive firing of brain neurons, with highly variable clinical and laboratory findings".

Examples of known types of seizures include partial seizures, such as simple partial seizures, complex partial seizures, and secondary generalized seizures; and no seizures, myoclonic seizures, clonic seizures, tonic clonic seizures, and cataplexy. Known types of refractory epilepsy include West syndrome, lanocoris syndrome, tuberous sclerosis, Dravet syndrome, and fragile X syndrome. The focus of epilepsy therapy is drug therapy with antiepileptic drugs (AEDs). The goal of epilepsy drugs is to eliminate seizures while avoiding the side effects of treatment. Treatment with antiepileptic drugs typically begins with a single agent. Monotherapy will generally be carried out using 2 or 3 different types of drugs and if no effect is found, combination therapy may be followed. About 70% of newly diagnosed epileptic patients can expect to have a remission episode treated with anti-epileptic drugs. While in the remaining 30% of patients, seizures are difficult to suppress even with current drug combination therapy. Therefore, there is a need to develop highly effective combination therapies.

Examples of commercially available drugs for the treatment of epilepsy include carbamazepine, ethosuximide, phenobarbital, phenytoin, eclampsia ketone, sodium valproate, zonisamide, felbamate, gabapentin, lamotrigine, topiramate, tiagabine, levetiracetam, oxcarbazepine, eslicarbazepine, pregabalin, lacosamide, rufinamide, trimethadione, sultam, acetazolamide, vigabatrin, benzodiazepineQuasi-drugs (such as clonazepam, clobazam, nitrazepam, and diazepam), perampanel, and retigabine (NPL 1). These existing antiepileptic drugs show their effects by inhibiting neuronal hyperexcitability.

One of the major problems in pharmacotherapy with antiepileptic drugs is toxic symptoms (symptoms include dizziness, nystagmus, diplopia, somnolence, vomiting, ataxia, neurosis, cachexia, and loss of consciousness) due to the inhibition of nerve function. For most conventional antiepileptic drugs, these side effects appear in a dose-dependent manner and their organization constitutes a major problem limiting the choice and dosage of therapeutic agents. It also significantly reduces the quality of life of epileptic patients who need to use these drugs for a long period of time. Lowering the dosage of the individual active ingredients of the combination may create a difference between the effective and neurotoxic doses, thus allowing a safer and more effective treatment not only in cases of resistance to drug treatment, but also in general cases of epilepsy.

It is reported that indan-1-ylsulfonamide derivatives such as N- [ (1S) -2,2,5, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl ] sulfonamide (hereinafter also referred to as "Compound (Ia)"), N- [ (1S) -2,2,4, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl ] sulfonamide (hereinafter also referred to as "Compound (Ib)"), and (+) N- (2,2,4,6, 7-pentafluoro-2, 3-dihydro-1H-inden-1-yl) sulfonamide (hereinafter also referred to as "Compound (Ic)") using formulae (Ia), (Ib), And (Ic) indicate) show an improvement effect of seizure severity (score) in a mouse ignition model (epilepsy model), and are useful as epilepsy therapeutic agents (PTL 1).

AMPA-type glutamate receptors play an important role in the generation of epileptic waves and their transmission through synapses. AMPA-type glutamate receptor antagonists inhibit the activity of post-synaptic AMPA-type glutamate receptors via glutamate, inhibit neuronal hyperexcitability and reduce seizures. To date, a number of AMPA-type glutamate receptor antagonists have been reported. As mentioned earlier, perampanel (3- (2-cyanophenyl) -5- (2-pyridyl) -1-phenyl-1, 2-dihydropyridin-2-one) (represented by formula (II), hereinafter also referred to as "compound (II)") which has been commercially available as a drug for the treatment of epilepsy is an AMPA-type glutamate receptor antagonist.

A dipyridamole compound including a compound represented by the formula (III) (hereinafter also referred to as "compound (III)") also shows an antagonistic action on AMPA-type glutamic acid receptors, and it is reported that the dipyridamole compound is very useful as an epilepsy therapeutic agent (PTL 2).

List of citations

Patent document

[ PTL 1] International patent publication No. WO 2013/191144

[ PTL 2] International patent publication No. WO 2017/82288

Non-patent document

[ NPL 1] Shrivastava et al, "An overview on anti-epileptic drugs" [ antiepileptic Drug overview ], Drug discovery and treatment ], Vol.6, No.4, pp.178-193, 2012

Disclosure of Invention

Technical problem

It is an object of the present invention to provide a combination pharmaceutical agent which exhibits a potent anticonvulsant effect and has potential for use as a therapeutic agent for epilepsy.

Solution to the problem

To address this problem, the inventors have conducted earnest investigations using a mouse voice-induced convulsion model and a rat lithium-pilocarpine status epilepticus model. As a result, it was found that the combination of an indan-1-ylsulfonamide derivative and an AMPA-type glutamic acid receptor antagonist significantly inhibited sound-induced convulsions in a mouse sound-induced convulsion model. After further studies using a rat lithium-pilocarpine model for status epilepticus, it was found that a combination of an indan-1-ylsulfonamide derivative and an AMPA-type glutamate receptor antagonist significantly inhibits the status epilepticus seizure, and thus the present invention was completed.

Specifically, the present invention relates to the following <1> to <14 >.

<1> a therapeutic agent for epilepsy, which uses N- [ (1S) -2,2,5, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl ] sulfonamide in combination

Or a pharmaceutically acceptable salt thereof, and an AMPA-type glutamate receptor antagonist.

<2> a therapeutic agent for epilepsy, which comprises simultaneously or separately administering N- [ (1S) -2,2,5, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl ] sulfonamide

Or a pharmaceutically acceptable salt thereof, and an AMPA-type glutamate receptor antagonist.

<3> a therapeutic agent for epilepsy, which comprises N- [ (1S) -2,2,5, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl ] sulfonamide

Or a pharmaceutically acceptable salt thereof, and an AMPA-type glutamate receptor antagonist.

<4> the therapeutic agent according to any one of the above <1> to <3>, wherein the AMPA-type glutamate receptor antagonist is a compound selected from the group consisting of:

3- (2-cyanophenyl) -5- (2-pyridyl) -1-phenyl-1, 2-dihydropyridin-2-one,

9- (2-chlorophenyl) -7- (pyridin-3-yl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

2-fluoro-6- (7- (5-methoxypyridin-3-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

2-fluoro-6- (7- (6-methylpyridin-3-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

9- (2-chloro-3-fluorophenyl) -7- (6-methylpyridin-3-yl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

2-fluoro-6- (7- (2-methoxypyrimidin-5-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

7- (pyridin-3-yl) -9- (2,3,5, 6-tetrafluorophenyl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

3- (8-oxo-7- (thiophen-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyridinecarbonitriles,

3- (8-oxo-7- (thiophen-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyrazine-2-carbonitrile,

9- (2-fluorophenyl) -7-phenyl-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

2- (7- (4-fluorophenyl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

3- (7- (4-fluorophenyl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyridinecarbonitrile,

3- (7- (2-fluorophenyl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyridinecarbonitrile,

3- (3-fluoro-8-oxo-7-phenyl-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyridinecarbonitriles,

2-fluoro-6- (3-fluoro-8-oxo-7- (pyridin-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

2-fluoro-6- (7- (5-fluoropyridin-3-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

2-fluoro-6- (10-fluoro-3-oxo-4- (pyridin-3-yl) -4, 5-dihydro-3H-benzopyran [3,4-b ] pyridin-2-yl) benzonitrile,

9- (2-chloro-3-fluorophenyl) -7- (5-fluoropyridin-3-yl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

2-fluoro-6- (8-oxo-7- (pyrimidin-5-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

3, 6-difluoro-2- (8-oxo-7- (pyridin-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

2- (7- (5-chloropyridin-3-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) -6-fluorobenzonitrile,

2-fluoro-6- (7- (2-methylpyrimidin-5-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile, and

9- (3-fluoro-2-tolyl) -7- (pyridin-3-yl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

<5> the therapeutic agent according to any one of the above <1> to <3>, wherein the AMPA-type glutamic acid receptor antagonist is 3- (2-cyanophenyl) -5- (2-pyridyl) -1-phenyl-1, 2-dihydropyridin-2-one

Or a pharmaceutically acceptable salt thereof.

<6> the therapeutic agent according to any one of the above <1> to <3>, wherein the AMPA-type glutamate receptor antagonist is a compound selected from the group consisting of:

9- (2-chlorophenyl) -7- (pyridin-3-yl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

2-fluoro-6- (7- (5-methoxypyridin-3-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

2-fluoro-6- (7- (6-methylpyridin-3-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

9- (2-chloro-3-fluorophenyl) -7- (6-methylpyridin-3-yl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

2-fluoro-6- (7- (2-methoxypyrimidin-5-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

7- (pyridin-3-yl) -9- (2,3,5, 6-tetrafluorophenyl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

3- (8-oxo-7- (thiophen-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyridinecarbonitriles,

3- (8-oxo-7- (thiophen-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyrazine-2-carbonitrile,

9- (2-fluorophenyl) -7-phenyl-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

2- (7- (4-fluorophenyl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

3- (7- (4-fluorophenyl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyridinecarbonitrile,

3- (7- (2-fluorophenyl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyridinecarbonitrile,

3- (3-fluoro-8-oxo-7-phenyl-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) pyridinecarbonitriles,

2-fluoro-6- (3-fluoro-8-oxo-7- (pyridin-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

2-fluoro-6- (7- (5-fluoropyridin-3-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

2-fluoro-6- (10-fluoro-3-oxo-4- (pyridin-3-yl) -4, 5-dihydro-3H-benzopyran [3,4-b ] pyridin-2-yl) benzonitrile,

9- (2-chloro-3-fluorophenyl) -7- (5-fluoropyridin-3-yl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

2-fluoro-6- (8-oxo-7- (pyrimidin-5-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b']Bipyridin-9-yl) benzonitrile,

3, 6-difluoro-2- (8-oxo-7- (pyridin-3-yl) -7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

2- (7- (5-chloropyridin-3-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) -6-fluorobenzonitrile,

2-fluoro-6- (7- (2-methylpyrimidin-5-yl) -8-oxo-7, 8-dihydro-6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile,

And 9- (3-fluoro-2-tolyl) -7- (pyridin-3-yl) -6H-pyrano [3,2-b:5,4-b' ] bipyridinyl-8 (7H) -one,

<7> the therapeutic agent according to any one of the above <1> to <3>, wherein the AMPA-type glutamic acid receptor antagonist is 2-fluoro-6- (3-fluoro-8-oxo-7- (pyridin-3-yl) -7, 8-dihydro-6H-pyrone [3,2-b:5,4-b' ] bipyridinyl-9-yl) benzonitrile

Or a pharmaceutically acceptable salt thereof.

<8> a process for the preparation of a compound by reaction with N- [ (1S) -2,25, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl ] sulfonamide

Or a pharmaceutically acceptable salt thereof, for use in combination with an AMPA-type glutamate receptor antagonist for the treatment of epilepsy.

<9>N- [ (1S) -2,25, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl]Sulfonamides

Or a pharmaceutically acceptable salt thereof, for the treatment of epilepsy by combination with an AMPA-type glutamate receptor antagonist.

<10> a method for treating epilepsy which comprises using N- [ (1S) -2,2,5, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl ] sulfonamide in combination

Or a pharmaceutically acceptable salt thereof, and an AMPA-type glutamate receptor antagonist.

<11> a pharmaceutical composition comprising N- [ (1S) -2,2,5, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl ] sulfonamide

Or a pharmaceutically acceptable salt thereof, an AMPA-type glutamate receptor antagonist, and an excipient.

<12> a kit comprising:

pharmaceutical composition comprising N- [ (1S) -2,2,5, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl ] sulfonamide

Or a pharmaceutically acceptable salt and excipient thereof, and

a pharmaceutical composition comprising an AMPA-type glutamate receptor antagonist and an excipient.

<13>Use of AMPA-type glutamate receptor antagonists for producing therapeutic agents for epilepsy by reaction with N- [ (1S) -2,25, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl]Sulfonamides

Or a pharmaceutically acceptable salt thereof.

<14> N- [ (1S) -2,2,5, 7-tetrafluoro-2, 3-dihydro-1H-inden-1-yl ] sulfonamide

Or a pharmaceutically acceptable salt thereof, for use in the production of a therapeutic agent for epilepsy by use in combination with an AMPA-type glutamate receptor antagonist.

The compounds represented by the formulae (III) to (XXIV) will hereinafter be collectively referred to as "compounds (III) to (XXIV)".

Advantageous effects of the invention

The present invention provides a medicament combining an indan-1-ylsulfonamide derivative and an AMPA-type glutamic acid receptor antagonist. The drug exhibits a more significant anti-epileptic effect than when each component is used alone, and it has the potential to be used as a therapeutic agent for epilepsy.

Drawings

Figure 1 shows the effect of the combination of compound (Ia) and compound (II) in the rat lithium-pilocarpine status epilepticus model for test example 2.

Figure 2 shows the effect of the combination of compound (Ia) and compound (XVI) in the rat lithium-pilocarpine status epilepticus model for test example 3.

Detailed Description

The present invention will now be explained in detail.

For example, the compound (Ia), (Ib), or (Ic), or a pharmaceutically acceptable salt thereof can be produced by the method described in PTL 1. For example, compound (II) or a pharmaceutically acceptable salt thereof can be produced by the method described in international patent publication No. WO 2006/004100. For example, the compounds (III) to (XXIV) or pharmaceutically acceptable salts thereof can be produced by the method described in PTL 2.

The "pharmaceutically acceptable salt" is not particularly limited as long as it is formed with the compound of the present invention, and specific examples include acid addition salts such as inorganic acid salts, organic acid salts, or acidic amino acid salts.

Examples of the inorganic acid salt include hydrochloride, hydrobromide, sulfate, nitrate, or phosphate. Examples of the salts of organic acids include acetate, succinate, fumarate, maleate, tartrate, citrate, lactate, stearate, benzoate, methylsulfonate, ethylsulfonate, and p-toluenesulfonate.

Examples of acidic amino acid salts include aspartate and glutamate.

The therapeutic agent of the present invention may contain compound (Ia), (Ib), or (Ic), or a pharmaceutically acceptable salt thereof, and an AMPA-type glutamate receptor antagonist (i.e., selected from the group consisting of compound (II) and compounds (III) to (XXIV), or pharmaceutically acceptable salts thereof (each represented by the formula)), and both are administered simultaneously or separately. The two formulations may also be placed in separate packages as a kit formulation. Both compounds may also be included in a single formulation.

The therapeutic agent of the present invention can be prepared by mixing a pharmaceutically acceptable additive and compound (Ia), (Ib), or (Ic) or a pharmaceutically acceptable salt thereof, and/or a compound selected from the group consisting of compound (II) and compounds (III) to (XXIV) or a pharmaceutically acceptable salt thereof. The therapeutic agent for epilepsy of the present invention can be produced by a known method, for example, a method described in general rules for Preparations of the Japanese Pharmacopoeia [ general rules for the preparation of the Japanese Pharmacopoeia ], 16 th edition.

The therapeutic agents of the present invention may be suitably administered to a patient in a suitable dosage form.

In the therapeutic agent of the present invention, the dose of compound (Ia), (Ib), or (Ic) or a pharmaceutically acceptable salt thereof will vary depending on the severity of symptoms, the age, sex, body weight, and sensitivity of the patient, the time and method of administration, and the type of pharmaceutical formulation, but generally the daily oral dose for an adult (60kg body weight) is 100 μ g to 5g, or alternatively 300 μ g to 3g, or alternatively 1mg to 1g, or the injectable administration is 30 μ g to 1g, alternatively 30 μ g to 500mg, or alternatively 50 μ g to 300mg, given once or in portions.

In the therapeutic agent of the present invention, the dose of the compound selected from the group consisting of compound (II) and compounds (III) to (XXIV) or a pharmaceutically acceptable salt thereof can be appropriately selected in the above-described manner. For oral administration to an adult (60kg body weight), daily administration is typically from 10 μ g to 500mg, alternatively from 30 μ g to 300mg, or yet alternatively from 50 μ g to 100mg, or for injectable administration is from 3 μ g to 100mg, alternatively from 10 μ g to 100mg, or yet alternatively from 10 μ g to 50mg, given in one portion or in portions.

The dose of compound (Ia), (Ib), or (Ic) or a pharmaceutically acceptable salt thereof (in the therapeutic agent of the present invention) and the dose of compound selected from the group consisting of compound (II) and compounds (III) to (XXIV) or a pharmaceutically acceptable salt thereof will vary depending on the severity of symptoms, the age, sex, body weight, and sensitivity of the patient, the time and method of administration, and the type of pharmaceutical formulation. Typically, for oral administration to an adult (60kg body weight), the daily administration of compound (Ia), (Ib), or (Ic) or a pharmaceutically acceptable salt thereof is 100 μ g to 5g, and the daily administration of a compound selected from the group consisting of compound (II) and compounds (III) to (XXIV) or a pharmaceutically acceptable salt thereof is 10 μ g to 500mg, given once or in portions. Alternatively, oral administration to an adult (60kg body weight), daily administration of compound (Ia), (Ib), or (Ic) or a pharmaceutically acceptable salt thereof is 300 μ g to 3g, and daily administration of a compound selected from the group consisting of compound (II) and compounds (III) to (XXIV) or a pharmaceutically acceptable salt thereof is 30 μ g to 300mg, given once or in portions. Still alternatively, for oral administration to an adult (60kg body weight), the daily administration of compound (Ia), (Ib), or (Ic) or a pharmaceutically acceptable salt thereof is 1mg to 1g, and the daily administration of a compound selected from the group consisting of compound (II) and compounds (III) to (XXIV) or a pharmaceutically acceptable salt thereof is 50 μ g to 100mg, given once or in portions. Typically, the daily administration of compound (Ia), (Ib), or (Ic) or a pharmaceutically acceptable salt thereof will be 30 μ g to 1g for injection administration to an adult (60kg body weight), and the daily administration of a compound selected from the group consisting of compound (II) and compounds (III) to (XXIV) or a pharmaceutically acceptable salt thereof will be 3 μ g to 100mg, given in one portion or in portions. Alternatively, the daily administration of compound (Ia), (Ib), or (Ic) or a pharmaceutically acceptable salt thereof may be 30 μ g to 500mg for injection administration to an adult (60kg body weight), and the daily administration of a compound selected from the group consisting of compound (II) and compounds (III) to (XXIV) or a pharmaceutically acceptable salt thereof will be 10 μ g to 100mg, given once or in portions. Still alternatively, the daily administration of compound (Ia), (Ib), or (Ic) or a pharmaceutically acceptable salt thereof may be 50 μ g to 300mg for injection administration to an adult (60kg body weight), and the daily administration of a compound selected from the group consisting of compound (II) and compounds (III) to (XXIV) or a pharmaceutically acceptable salt thereof will be 10 μ g to 50mg, given once or in portions. Examples of the invention

[ pharmacological test example ]

The inventors studied using a mouse sound-induced convulsion model to confirm the suppression of seizures. We also performed studies using the rat lithium-pilocarpine status epilepticus model to demonstrate the inhibitory effect on status epilepticus seizures.

Test example 1 confirmation test of inhibitory effect against convulsions using mouse voice-induced convulsion model

A mouse voice-induced convulsion model test was performed to confirm the inhibitory effect on convulsions. Sound-stimulation-induced tonic convulsions were used as evaluation indices in this model (European Journal of Pharmacology [ European Journal of Pharmacology ],222, p.193-203 (1992)).

< method >

Three-week-old male DBA/2JJcl mice (clean japan) were provided for testing (n-5 for each treatment, twice). Sound-stimulus-induced tonic convulsions were used as evaluation index (see the above publication).

Compound (Ia) and/or compound (II) were dissolved in 0.4% methylcellulose/5% hydrogenated castor oil/5% 1N hydrochloric acid/10% dimethylsulfoxide solution (each at an administration dose of 20 mL/kg) to prepare samples for oral administration. A mixed solution without compound (vehicle) was used as a negative control. The compositions of the groups are shown in table 1. Sound stimulation (11kHz, 115dB, duration: 30 seconds) was performed for 30 minutes after the sample was administered to induce convulsions. Immediately after cessation of the sound stimulation, tonic convulsions were assessed by observing the presence or absence of hindlimb extension. The percentage showing tonic convulsions (% tonic convulsions) in each administration group was calculated.

Based on the calculated% tonic convulsions, 50% effective doses of the group administered with compound (Ia) alone, the group administered with compound (II) alone, and the group administered with a combination of compound (Ia) and compound (II) (compound (Ia) ED50, compound (II) ED50, and ED50mix, respectively) were calculated by regression analysis. The theoretical addition ED50 value (ED50 add) was calculated and evaluated using isobaric mapping according to the method described in the literature (Epilepsia,44, page 1003-.

< results >

ED50 for each administration group in the mouse voice-induced convulsion model is shown in table 2. The calculated theoretical added ED50 value (ED50 add) was 26 mg/kg. Since the ED50mix/ED50add ratio result was 0.58 (table 3), it was confirmed that the combination of compound (Ia) and compound (II) showed a synergistic anticonvulsant effect. The results show that the medicine of the invention shows significant inhibition effect on convulsion.

[ Table 1]

Group number	Treatment of
		1	Media
2	25mg/kg Compound (Ia)
		3	50mg/kg of Compound (Ia)
4	100mg/kg of Compound (Ia)
		5	200mg/kg Compound (Ia)
6	0.125mg/kg Compound (II)
		7	0.25mg/kg Compound (II)
8	0.5mg/kg Compound (II)
		9	1mg/kg Compound (II)
10	7.5mg/kg of Compound (Ia) +0.05mg/kg of Compound (II)
		11	15mg/kg of Compound (Ia) +0.1mg/kg of Compound (II)
12	30mg/kg of Compound (Ia) +0.2mg/kg of Compound (II)
		13	60mg/kg of Compound (Ia) +0.4mg/kg of Compound (II)

[ Table 2]

Compound (I)	ED50
		(Ia)	53mg/kg
(II)	0.33mg/kg
		(Ia)+(II)	15mg/kg

[ Table 3]

ED50mix	15mg/kg
		ED50add	26mg/kg
Ratio (ED50mix/ED50add)	0.58
		Evaluation of	Synergistic effect

Test example 2 confirmation test of inhibition of epileptic seizure Using rat lithium-pilocarpine status epilepticus model (1)

A rat lithium-pilocarpine status epilepticus model test was performed to confirm the inhibitory effect on status epilepticus seizures. In this model, the peak level of drug-induced brain waves was used as an evaluation index (Journal of neuroscience Methods, 172, pp.143-157 (2008)).

< method >

EEG electrodes were embedded into the skull under anesthesia with a three-component mixture (2mg/kg midazolam, 0.15mg/kg medetomidine hydrochloride, 2.5mg/kg butorphanol tartrate, administered subcutaneously). At least two days after surgery, lithium chloride (127mg/kg dose, 1mL/kg administration volume) was administered intraperitoneally. One day later, pilocarpine hydrochloride (30mg/kg dose, 5mL/kg administration volume) and (-) -scopolamine methylbromide (5mg/kg dose, 1mL/kg volume) were administered intraperitoneally in a continuous manner to induce seizures. Only animals exhibiting seizures with seizure scores of 4 or higher were used in the experiment. Table 4 shows the relationship between seizure scores and symptoms. 30 minutes after visual confirmation of a seizure score of 4 or more, the vehicle or sample was administered to the tail vein (administration volume: 1mL/kg, injection rate: rinsing). The compositions of the groups are shown in table 5. Brain waves were recorded continuously until 1h after vehicle or sample administration. Brain wave analysis software (SleepSign, Nagano Prefecture, by Kissei comec ltd.) was used to calculate each individual brain wave data for each set period (4 seconds/period) (analysis target frequency ≧ 5Hz,<100Hz) total power (μ V)²). After excluding the period containing noise due to animal movement, the 10 minute period prior to administration was targeted and the average power per frequency (μ V) per period was calculated²) After which all bands are summed to obtain each individual front total power (μ V)²). FFT analysis was performed after 1 hour application in the same manner to calculate the total post-power (. mu.V) of each individual²). The percentage of each individual back total power relative to the front total power ((back total power/front total power) × 100) was calculated and statistically analyzed. Statistical significance was determined between the vehicle group and the group administered the combination of compound (Ia) and compound (II) by unpaired t-test. Fisher LSD detection was performed on important examples after one-way anova to determine statistical significance between the group administered compound (Ia) alone and the group administered compound (II) alone, and the group administered a combination of compound (Ia) and compound (II). In both cases, the significance level was considered to be 5%.

< results >

Figure 1 shows the effect of the combination of compound (Ia) and compound (II) in a rat lithium-pilocarpine status epilepticus model. The group administered with the combination of compound (Ia) and compound (II) exhibited a significant seizure inhibitory effect compared to the vehicle group. The group administered with the combination of compound (Ia) and compound (II) exhibited a significant increase in seizure inhibitory effect even compared to the group administered with compound (Ia) alone and the group administered with compound (II) alone. This result indicates that the drug of the present invention has a significant seizure inhibitory effect on the status epilepticus seizures.

Test example 3 confirmation test of inhibition of epileptic seizure Using rat lithium-pilocarpine epileptic status model (2)

A rat lithium-pilocarpine status epilepticus model test was performed to confirm the inhibitory effect on status epilepticus seizures.

< method >

Male SD rats (Charles River Laboratories, japan) at six weeks of age were provided for testing. Lithium chloride was administered intraperitoneally (127mg/kg dose, 1mL/kg administration volume). One day later, pilocarpine hydrochloride (30mg/kg dose, 5mL/kg administration volume) and (-) -scopolamine methylbromide (5mg/kg dose, 1mL/kg volume) were administered intraperitoneally in a continuous manner to induce seizures. Only animals showing an attack score of 4 or higher were used for the experiments. Table 4 shows the relationship between seizure scores and symptoms. 30 minutes after visual confirmation of an attack score of 4 or more, the vehicle or sample was injected into the tail vein (administration volume: 1-4mL/kg, injection rate: flush). The compositions of the groups are shown in table 6. As shown in table 4, seizures were scored 1 hour after compound administration. Statistical significance between the vehicle group and the group given compound (Ia) alone, the group given compound (XVI) alone, and the group given a combination of compound (Ia) and compound (XVI) was determined by the Holm-Sidak statistical test. Statistical significance between the group given compound (Ia) alone and the group given compound (XVI) alone, and the group given a combination of compound (Ia) and compound (XVI) was also determined by the Holm-Sidak statistical test. In both cases, the significance level was considered to be 5%.

< results >

Figure 2 shows the effect of the combination of compound (Ia) and compound (XVI) in a rat lithium-pilocarpine status epilepticus model. The group administered with the combination of compound (Ia) and compound (XVI) exhibited a significant seizure inhibitory effect compared to the vehicle group. The group administered with the combination of compound (Ia) and compound (XVI) exhibited a significant increase in seizure inhibitory effect even compared to the group administered with compound (Ia) alone and the group administered with compound (XVI) alone. This result indicates that the drug of the present invention has a significant seizure inhibitory effect on the status epilepticus seizures.

[ Table 4]

Seizure score	Symptoms and signs
		0	Without attack
1	Mild facial clonus and blinking
		2	Severe facial clonus, shaking head and chewing
3	Unilateral or alternating forelimb clonus
		4	Bilateral forelimb clonus and stance
5	Bilateral forelimb clonus with standing and falling

[ Table 5]

Group number	Treatment of
		1	Media
2	75mg/kg Compound (Ia)
		3	1mg/kg Compound (II)
4	75mg/kg of Compound (Ia) +1mg/kg of Compound (II)

[ Table 6]

Group number	Treatment of
		1	Media
2	75mg/kg Compound (Ia)
		3	2mg/kg Compound (XVI)
4	75mg/kg of Compound (Ia) +2mg/kg of Compound (XVI)